EU-X-CT project to clarify cross-border trial access in Europe

At present, cross-border trial access is a real grey area in Europe, making it difficult for sponsors to run trials, especially in rare diseases. Having clear-cut guidance in place would make it easier for sponsors to understand how they should go about enrolling patients who are from different countries to where the trial site is located. In the Q&A with Clinical Trials Arena, Worldwide’s Sarah Bly, Director of Regulatory Science Strategy and Innovation and Matt Cooper, Executive Director and Therapeutic Strategy Lead, Oncology, discuss the EU-X-CT project. Read more here.